Clik here to view.
Galera Therapeutics Announces Dosing of First Patient in Phase 1/2 Pancreatic...
MALVERN, Penn. — Feb. 28, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer...
View ArticleGalera Therapeutics Announces Preclinical Data Demonstrating Potential of...
Galera AACR Press Release 04-16-18 FINALMALVERN, Penn. — Apr. 16, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with...
View ArticleClik here to view.
Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical...
MALVERN, Penn. — May 16, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer...
View ArticleClik here to view.
Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419...
MALVERN, Penn. — June 3, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical...
MALVERN, Penn. — June 12, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419...
MALVERN, Penn. — June 29, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Galera Therapeutics Presents Structure and Synthesis of GC4419 at American...
MALVERN, Penn. — Aug. 20, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and...
MALVERN, Penn. — September 19, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3...
MALVERN, Penn. — October 15, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem...
MALVERN, Penn. — October 23, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical...
MALVERN, Penn. — March 21, 2019 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to...
View ArticleClik here to view.
Galera Therapeutics Announces Two-Year Tumor Outcomes Data for GC4419
MALVERN, Penn. — October 8, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that...
View ArticleClik here to view.
Galera Therapeutics Appoints Christopher Degnan as Chief Financial Officer
MALVERN, Penn. — October 10, 2019 — Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that...
View Article
